Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 136236-52-7
2. B9a329cn07
3. (2r,3r)-2,3-dihydroxybutanedioic Acid;(1r)-n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine
4. Unii-b9a329cn07
5. Rasagiline (tn)
6. Rasagiline Hemitartrate
7. Schembl2031233
8. Rasagiline Tartrate [who-dd]
9. D10829
10. Q27274543
11. 1-h-inden-1-amine, 2,3-dihydro-n-2-propyn-1-yl-, 1(r)-, (2r,3r)-2,3-dihydroxybutanedioate (2:1)
12. 950981-99-4
Molecular Weight | 492.6 g/mol |
---|---|
Molecular Formula | C28H32N2O6 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 492.22603674 g/mol |
Monoisotopic Mass | 492.22603674 g/mol |
Topological Polar Surface Area | 139 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 346 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
NDC Package Code : 64552-4044
Start Marketing Date : 2006-05-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2020-05-04
Registration Number : Number 1673-33-ND
Manufacturer Name : Interquim, SA
Manufacturer Address : c/ Joan Buscalla, 10, 08173 Sant Cugat del Vallaes (Barcelona), Spain
Available Reg Filing : ASMF |
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
Date of Issue : 2022-11-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0182
Address of the Firm :
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm : Chemical Technical Operations Unit-VI, APIIC Industrial Estate, Pydibhimavaram V...
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat
Date of Issue : 2022-11-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0182
Address of the Firm : Sy.no. 239 and 240 Dothigudem Village, Pochampally mandal, Nalgonda, District-50...
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
Registrant Name : Kyungbo Pharmaceutical Co., Ltd.
Registration Date : 2020-05-04
Registration Number : Number 1673-33-ND
Manufacturer Name : Interquim, SA
Manufacturer Address : c/ Joan Buscalla, 10, 08173 Sant Cugat del Vallaes (Barcelona), Spain
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
NDC Package Code : 64552-4044
Start Marketing Date : 2006-05-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.
About the Company : Interquim, founded in 1978, is now part of the Ferrer HealthTech division. Interquim specializes in the development of competitive processes for manufacturing high added-value APIs...
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...
About the Company : Amino Chemicals Ltd. manufactures high quality bulk active ingredients to support its customers for the earliest possible launch of generic pharmaceutical products into regulated m...
About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...
About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...
About the Company : Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India. Indoco has a strong int...
About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
99
PharmaCompass offers a list of Rasagiline Tartrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rasagiline Tartrate manufacturer or Rasagiline Tartrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rasagiline Tartrate manufacturer or Rasagiline Tartrate supplier.
PharmaCompass also assists you with knowing the Rasagiline Tartrate API Price utilized in the formulation of products. Rasagiline Tartrate API Price is not always fixed or binding as the Rasagiline Tartrate Price is obtained through a variety of data sources. The Rasagiline Tartrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rasagiline Tartrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rasagiline Tartrate, including repackagers and relabelers. The FDA regulates Rasagiline Tartrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rasagiline Tartrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rasagiline Tartrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rasagiline Tartrate supplier is an individual or a company that provides Rasagiline Tartrate active pharmaceutical ingredient (API) or Rasagiline Tartrate finished formulations upon request. The Rasagiline Tartrate suppliers may include Rasagiline Tartrate API manufacturers, exporters, distributors and traders.
click here to find a list of Rasagiline Tartrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rasagiline Tartrate Drug Master File in Korea (Rasagiline Tartrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rasagiline Tartrate. The MFDS reviews the Rasagiline Tartrate KDMF as part of the drug registration process and uses the information provided in the Rasagiline Tartrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rasagiline Tartrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rasagiline Tartrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rasagiline Tartrate suppliers with KDMF on PharmaCompass.
A Rasagiline Tartrate written confirmation (Rasagiline Tartrate WC) is an official document issued by a regulatory agency to a Rasagiline Tartrate manufacturer, verifying that the manufacturing facility of a Rasagiline Tartrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rasagiline Tartrate APIs or Rasagiline Tartrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Rasagiline Tartrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Rasagiline Tartrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rasagiline Tartrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rasagiline Tartrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rasagiline Tartrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rasagiline Tartrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rasagiline Tartrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rasagiline Tartrate suppliers with NDC on PharmaCompass.
Rasagiline Tartrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rasagiline Tartrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rasagiline Tartrate GMP manufacturer or Rasagiline Tartrate GMP API supplier for your needs.
A Rasagiline Tartrate CoA (Certificate of Analysis) is a formal document that attests to Rasagiline Tartrate's compliance with Rasagiline Tartrate specifications and serves as a tool for batch-level quality control.
Rasagiline Tartrate CoA mostly includes findings from lab analyses of a specific batch. For each Rasagiline Tartrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rasagiline Tartrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Rasagiline Tartrate EP), Rasagiline Tartrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rasagiline Tartrate USP).